Chuong D. Hoang, M.D., FACS
Dr. Chuong D. Hoang is a surgeon-scientist at the National Cancer Institute in Bethesda, Maryland. He works in molecular therapeutics to research promising therapeutic microRNAs for use against thoracic cancers like malignant pleural mesothelioma and lung cancer. His work facilitates projects aimed at discovering biomarkers for diagnosis, prognosis, and response evaluation.[1]
Dr. Hoang’s lab specifically uses malignant pleural mesothelioma as a model for integrating and validating its works, though other thoracic cancers are also of interest. His clinical expertise includes all major aspects of thoracic surgery, including minimally invasive techniques, video-assisted thoracic surgery and robotic surgery, and endoscopic surgery.[1]
Education and Career
Dr. Hoang earned his medical degree at the University of Minnesota Medical School. He remained at the University of Minnesota to complete an internship and residency in General Surgery, during which time his research was supported by the Ruth L. Kirschstein National Research Service Award and a Training Program Grant in the Division of Hematology-Oncology. After completing this portion of his education and training, he completed a cardiothoracic residency at the University of Pennsylvania with an emphasis on thoracic surgery.[1]
After finishing his medical training and education, Dr. Hoang served on the faculty at Stanford University School of Medicine as an Assistant Professor. He was named Medical co-director of the Stanford Cancer Center Tissue Bank and established an independent thoracic oncology laboratory there to investigate the metabolic derangements in lung cancer and microRNA interactions in mesothelioma.[1]
Professional Memberships
Dr. Hoang is a member of several professional organizations, including:[1]
- American Association for Thoracic Surgery
- Cardiothoracic Surgery Network
- The Society of Thoracic Surgeons
- Western Thoracic Surgical Association
Research
Dr. Hoang’s research interest centers on developing novel biomarkers and therapeutic strategies for the treatment of thoracic malignancies including pleural mesothelioma, thymic epithelial tumors, and non-small cell lung carcinoma. His two main projects focus on oncogenesis modeling and miRNA-based therapy.[1]
Some of Dr. Hoang’s notable publications include:[1]
Surface-fill hydrogel attenuates the oncogenic signature of complex anatomical surface cancer in a single application Poulami Majumder, Anand Singh, Ziqiu Wang, Kingshuk Dutta, Roma Pahwa, Chen Liang, Caroline Andrews, Nimit L Patel, Junfeng Shi, Natalia de Val, Scott T R Walsh, Albert Byungyun Jeon, Baktiar Karim, Chuong D Hoang, Joel P Schneider. Nature Nanotechnology. 2021. [ Journal Article ]
MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis Anand Singh, Nathanael Pruett, Roma Pahwa, Arushi P Mahajan, David S Schrump, Chuong D Hoang. Molecular Therapy Nucleic Acids. 24: 669-681, 2021. [ Journal Article ]
Normal mesothelial cell lines newly derived from human pleural biopsy explants Nathanael Pruett, Anand Singh, Ahjeetha Shankar, David S Schrump, Chuong D Hoang. American Journal of Physiology Lung Cellular and Molecular Physiology. 319(4): L652-L660, 2020. [ Journal Article ]
MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis Singh A, Bhattacharyya N, Srivastava A, Pruett N, Ripley RT, Schrump DS, Hoang CD. Molecular Therapy. 27(9): 1665-1680, 2019. [ Journal Article]
Metadherin Is a Prognostic Apoptosis Modulator in Mesothelioma Induced via NF-κB-Mediated Signaling. Zhang L, Singh A, Plaisier C, Pruett N, Ripley RT, Schrump DS, Hoang CD. Translational Oncology. 12(6): 859-870, 2019. [ Journal Article]
